North America Ophthalmic Drugs Market 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $1,500	116 Pages	Triton Market Research	April, 2024	TRTN18748655

Best Price Guarantee
Price	from $1,500
Length	116 Pages
Publisher	Triton Market Research
Published Date	April, 2024
SKU	TRTN18748655

North America Ophthalmic Drugs Market 2023-2030

Market Outlook

Triton’s research report predicts that the North American ophthalmic drugs market is set to attain growth at a CAGR of 6.09% during the 2023-2030 forecast period. Canada and the United States are analyzed in this report.

The United States is witnessing steady growth in the ophthalmic drugs market. An increasing prevalence of eye diseases, advancements in the technology of drug delivery, investments and focus on R&D, and an aging population with poor eye health collectively influence the demand for ophthalmic drugs. Moreover, conditions like glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and dry eye syndrome led to a rise in the use of ophthalmic drugs.

The ophthalmic drugs market in Canada is on a positive growth trajectory due to a significant improvement in creating alternatives for eye care treatment. Gene therapies, advanced surgical techniques, cell-based therapies, cataract surgery, and laser vision correction are some innovations introduced for curing eye disorders. Additionally, research institutes and pharma companies also participate in developing novel treatments with precision to provide specialized eye care services in hospitals and eye clinics. These factors together contribute to propel the ophthalmic drugs market.

Competitive Outlook

The key companies listed in the ophthalmic drugs market are Johnson & Johnson, Accutome Inc, Regeneron Pharmaceuticals Inc, Genentech Inc, and Bausch Health Companies Inc.

1. North America Ophthalmic Drugs Market - Summary
2. Industry Outlook: 2.1. Technology Snapshot; 2.2. Impact Analysis On The Ophthalmic Drugs Market; 2.2.1. Covid-19 Impact On The Ophthalmic Drugs Market; 2.3. Porter’s Five Forces Analysis; 2.3.1. Threat Of New Entrants; 2.3.2. Threat Of Substitutes; 2.3.3. Bargaining Power Of Buyers; 2.3.4. Bargaining Power Of Suppliers; 2.3.5. Threat Of Competitive Rivalry; 2.4. Market Maturity Analysis; 2.5. Regulatory Framework; 2.6. Key Buying Impact Analysis; 2.7. Key Market Strategies; 2.7.1. Collaborations; 2.7.2. Product Launches; 2.7.3. Mergers & Acquisitions; 2.8. Market Drivers; 2.8.1. Aging; 2.8.2. Progress In Drug Delivery Technologies; 2.8.3. Escalating Incidence Of Ocular Diseases; 2.8.4. Reimbursement Policies By Healthcare Systems; 2.9. Market Challenges; 2.9.1. Challenging Timelines For Product Approval; 2.9.2. Adverse Effects Associated With Ophthalmic Drug Usage; 2.10. Market Opportunities; 2.10.1. Surge In Interest Regarding Topically Administered Ophthalmic Drugs; 2.10.2. Increase In Approvals For Innovative Ophthalmic Therapies; 2.11. Analyst Perspective
3. North America Ophthalmic Drugs Market – By Type: 3.1. Prescription Drugs; 3.2. Over-the-counter Drugs
4. North America Ophthalmic Drugs Market – By Condition: 4.1. Dry Eye; 4.2. Glaucoma; 4.3. Infection/Inflammation/Allergies; 4.4. Retinal Disorder; 4.4.1. Wet-age Related Macular Degeneration; 4.4.2. Dry-age Related Macular Degeneration; 4.4.3. Diabetic Retinopathy; 4.4.4. Other Retinal Disorders; 4.5. Other Conditions
5. North America Ophthalmic Drugs Market – By Therapeutic Type: 5.1. Anti-glaucoma; 5.2. Anti-infection; 5.3. Anti-inflammatory; 5.4. Anti-allergy; 5.5. Other Therapeutic Types
6. North America Ophthalmic Drugs Market – By Delivery Method: 6.1. Gels; 6.2. Eye Solutions & Suspensions; 6.3. Capsules & Tablets; 6.4. Eye Drops; 6.5. Ointments
7. North America Ophthalmic Drugs Market – By Channel: 7.1. Hospital Pharmacies; 7.2. Drug Stores; 7.3. Online Pharmacies; 7.4. Other Channels
8. North America Ophthalmic Drugs Market – Country Outlook: 8.1. United States; 8.1.1. United States Ophthalmic Drugs Market Forecast & Prospects; 8.2. Canada; 8.2.1. Canada Ophthalmic Drugs Market Forecast & Prospects
9. Competitive Landscape: 9.1. Abbvie Inc; 9.1.1. Overview; 9.1.2. Product Portfolio; 9.1.3. Key Strengths; 9.1.4. Key Challenges; 9.2. Bausch Health Companies Inc; 9.2.1. Overview; 9.2.2. Product Portfolio; 9.2.3. Key Strengths; 9.2.4. Key Challenges; 9.3. Johnson & Johnson; 9.3.1. Overview; 9.3.2. Product Portfolio; 9.3.3. Key Strengths; 9.3.4. Key Challenges; 9.4. Novartis Ag; 9.4.1. Overview; 9.4.2. Product Portfolio; 9.4.3. Key Strengths; 9.4.4. Key Challenges; 9.5. Regeneron Pharmaceuticals Inc; 9.5.1. Overview; 9.5.2. Product Portfolio; 9.5.3. Key Strengths; 9.5.4. Key Challenges; 9.6. Sun Pharmaceutical Industries Ltd; 9.6.1. Overview; 9.6.2. Product Portfolio; 9.6.3. Key Strengths; 9.6.4. Key Challenges; 9.7. Accutome Inc; 9.7.1. Overview; 9.7.2. Product Portfolio; 9.7.3. Key Strengths; 9.7.4. Key Challenges; 9.8. Genentech Inc; 9.8.1. Overview; 9.8.2. Product Portfolio; 9.8.3. Key Strengths; 9.8.4. Key Challenges; 9.9. Thea Pharma Inc; 9.9.1. Overview; 9.9.2. Product Portfolio; 9.9.3. Key Strengths; 9.9.4. Key Challenges; 9.10. Pfizer Inc; 9.10.1. Overview; 9.10.2. Product Portfolio; 9.10.3. Key Strengths; 9.10.4. Key Challenges
10. Research Methodology & Scope: 10.1. Research Scope & Deliverables; 10.2. Sources Of Data; 10.3. Research Methodology
Tables List: Table 1: North America Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 2: Regulatory Framework; Table 3: List Of Collaborations; Table 4: List Of Product Launches; Table 5: List Of Mergers & Acquisitions; Table 6: North America Ophthalmic Drugs Market, By Country Outlook, 2023-2030 (In $ Million); Table 7: North America Ophthalmic Drugs Market, By Type, 2023-2030 (In $ Million); Table 8: North America Ophthalmic Drugs Market, By Condition, 2023-2030 (In $ Million); Table 9: North America Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Table 10: North America Ophthalmic Drugs Market, By Therapeutic Type, 2023-2030 (In $ Million); Table 11: North America Ophthalmic Drugs Market, By Delivery Method, 2023-2030 (In $ Million); Table 12: North America Ophthalmic Drugs Market, By Channel, 2023-2030 (In $ Million)
Figures List: Figure 1: Technology Snapshot; Figure 2: Market Maturity Analysis; Figure 3: North America Ophthalmic Drugs Market, By Type, 2022 & 2030 (In %); Figure 4: North America Ophthalmic Drugs Market, By Prescription Drugs, 2023-2030 (In $ Million); Figure 5: North America Ophthalmic Drugs Market, By Over-the-counter Drugs, 2023-2030 (In $ Million); Figure 6: North America Ophthalmic Drugs Market, By Condition, 2022 & 2030 (In %); Figure 7: North America Ophthalmic Drugs Market, By Dry Eye, 2023-2030 (In $ Million); Figure 8: North America Ophthalmic Drugs Market, By Glaucoma, 2023-2030 (In $ Million); Figure 9: North America Ophthalmic Drugs Market, By Infection/Inflammation/Allergies, 2023-2030 (In $ Million); Figure 10: North America Ophthalmic Drugs Market, By Retinal Disorder, 2023-2030 (In $ Million); Figure 11: North America Ophthalmic Drugs Market, By Retinal Disorder, 2022 & 2030 (In %); Figure 12: North America Ophthalmic Drugs Market, By Wet Age-related Macular Degeneration, 2023-2030 (In $ Million); Figure 13: North America Ophthalmic Drugs Market, By Dry Age-related Macular Degeneration, 2023-2030 (In $ Million); Figure 14: North America Ophthalmic Drugs Market, By Diabetic Retinopathy, 2023-2030 (In $ Million); Figure 15: North America Ophthalmic Drugs Market, By Other Retinal Disorders, 2023-2030 (In $ Million); Figure 16: North America Ophthalmic Drugs Market, By Other Conditions, 2023-2030 (In $ Million); Figure 17: North America Ophthalmic Drugs Market, By Therapeutic Type, 2022 & 2030 (In %); Figure 18: North America Ophthalmic Drugs Market, By Anti-glaucoma, 2023-2030 (In $ Million); Figure 19: North America Ophthalmic Drugs Market, By Anti-infection, 2023-2030 (In $ Million); Figure 20: North America Ophthalmic Drugs Market, By Anti-inflammatory, 2023-2030 (In $ Million); Figure 21: North America Ophthalmic Drugs Market, By Anti-allergy, 2023-2030 (In $ Million); Figure 22: North America Ophthalmic Drugs Market, By Other Therapeutic Types, 2023-2030 (In $ Million); Figure 23: North America Ophthalmic Drugs Market, By Delivery Method, 2022 & 2030 (In %); Figure 24: North America Ophthalmic Drugs Market, By Gels, 2023-2030 (In $ Million); Figure 25: North America Ophthalmic Drugs Market, By Eye Solutions & Suspensions, 2023-2030 (In $ Million); Figure 26: North America Ophthalmic Drugs Market, By Capsules & Tablets, 2023-2030 (In $ Million); Figure 27: North America Ophthalmic Drugs Market, By Eye Drops, 2023-2030 (In $ Million); Figure 28: North America Ophthalmic Drugs Market, By Ointments, 2023-2030 (In $ Million); Figure 29: North America Ophthalmic Drugs Market, By Channel, 2022 & 2030 (In %); Figure 30: North America Ophthalmic Drugs Market, By Hospital Pharmacies, 2023-2030 (In $ Million); Figure 31: North America Ophthalmic Drugs Market, By Drug Stores, 2023-2030 (In $ Million); Figure 32: North America Ophthalmic Drugs Market, By Online Pharmacies, 2023-2030 (In $ Million); Figure 33: North America Ophthalmic Drugs Market, By Other Channels, 2023-2030 (In $ Million); Figure 34: North America Ophthalmic Drugs Market, By Country Outlook, 2022 & 2030 (In %); Figure 35: United States Ophthalmic Drugs Market, 2023-2030 (In $ Million); Figure 36: Canada Ophthalmic Drugs Market, 2023-2030 (In $ Million)